Valuation: Monopar Therapeutics Inc.

Market Cap 487M 435M 402M 364M 681M 46.25B 693M 4.84B 1.91B 24.23B 1.83B 1.79B 76.39B P/E 2026 *
-29.3x
P/E 2027 * -29x
Enterprise Value 368M 329M 304M 275M 515M 34.97B 524M 3.66B 1.45B 18.32B 1.38B 1.35B 57.77B EV / Sales 2026 *
-
EV / Sales 2027 * 12.1x
Free-Float
76.53%
Yield 2026 *
-
Yield 2027 * -
1 day-3.21%
1 week+1.13%
Current month-12.07%
1 month-21.63%
3 months-33.73%
6 months+31.57%
Current year+7.27%
1 week 69.48
Extreme 69.48
75.08
1 month 68.8
Extreme 68.805
90.05
Current year 50.07
Extreme 50.07
124.82
1 year 50.07
Extreme 50.07
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer 64 31/08/2026
Director TitleAgeSince
Director/Board Member 42 30/11/2014
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Exercice

Founder

25,200 0.3754%
30/09/26 Exercice

Chief Operating Officer

10,712 0.1596%
30/09/26 Exercice

Founder

23,946 0.3568%
Change 5-day change 1-year change 3-year change Capi.($)
-3.21%+1.13%-13.83%+3,009.88% 487M
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+7.50%+11.01%+73.48% 54.89B
+0.57%+4.60%+10.07%+92.86% 53.28B
+0.17%+4.25%+26.52%+51.46% 45.81B
-1.38%+2.19%+21.64%+123.51% 43.46B
-0.03%+5.59%+251.61%+923.70% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+5.68%+36.43%+27.54% 23.76B
Average -0.08%+0.40%+42.92%+442.95% 38.24B
Weighted average by Cap. +0.37%+0.55%+47.52%+163.10%

Financials

2026 *2027 *
Net sales - 28.26M 25.24M 23.31M 21.13M 39.53M 2.68B 40.18M 281M 111M 1.41B 106M 104M 4.43B
Net income -21.46M -19.17M -17.71M -16.05M -30.02M -2.04B -30.52M -213M -84.36M -1.07B -80.55M -78.84M -3.37B -26.62M -23.77M -21.96M -19.9M -37.23M -2.53B -37.84M -264M -105M -1.32B -99.89M -97.77M -4.17B
Net Debt -119M -106M -97.97M -88.78M -166M -11.27B -169M -1.18B -467M -5.91B -446M -436M -18.62B -145M -129M -119M -108M -202M -13.72B -206M -1.44B -568M -7.19B -543M -531M -22.67B
Projected Income Statement - Annual - Monopar Therapeutics Inc.
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
23/10/26 US$70.73 -2.55% 40,216
22/10/26 US$72.58 +0.32% 122,555
21/10/26 US$72.35 -2.53% 87,275
20/10/26 US$74.23 +3.86% 89,532
19/10/26 US$71.47 +3.18% 73,776
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Monopar Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
72.58USD
Average target price
129.92USD
Spread / Average Target
+79.00%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Monopar Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. MNPR Stock